肝脏转运体介导的与口服降糖药相关药物相互作用研究进展

Progress in Liver Transporter-Mediated Drug Interactions with Oral Antidiabetic Agents

目的综述肝脏转运体介导的与口服降糖药相关的药物相互作用。方法通过查找近10年相关文献资料对肝脏转运体介导的与口服降糖药相关的药物相互作用进行总结阐述。结果口服降糖药是治疗2型糖尿病的首选药物,糖尿病患者在服用口服降糖药的同时常服用其他多种药物治疗相关疾病,这使药物相互作用发生的概率升高。多数口服降糖药在体内需经过肝脏,肝脏中除含有丰富的代谢酶外还含有多种转运体,当口服降糖药与合用药物分享相同肝脏转运体时,药物相互作用发生概率升高,是引起与口服降糖药相关的药物相互作用的重要因素之一。结论肝脏转运蛋白介导的与口服降糖药相关的药物相互作用是普遍存在的,为了减少糖尿病患者因同时服用多种药物而产生的不良反应,促进临床合理用药,有必要对肝脏转运体介导的与口服降糖药相关的药物相互作用进行深入研究。

OBJECTIVE To summarize the liver transporter-mediated drug interactions with oral antidiabetic agents. METHODS The related documentations in near ten years were searched and useful information to clarify liver transporter-mediated drug interac- tions with oral antidiabetic agents was summarized. RESULTS The drugs of first choice for treatmenting type 2 diabetes are oral an- tidiabetic agents. In clinic, oral antidiabetic agents often co-administrate with other drugs which may cause the rate of drug-drug inter- action increasing. In vivo, amount of oral antidiabetic agents are distributed in liver where exist may kinds of metabolic enzymes and transporters, when drugs were transported by same liver transporter, the rate of drug-drug interactions will increase. So transporters me- diated drug interaction is one of tile main mechanism in drug interation with oral antidiahetic agents. CONCLUSION Liver transport- ers play important role in drug interactions with oral antidiabetic agents, for decreasing rate of drug-drug interactions and promoting rational use of drug, it is necessary to review and research the liver transporter-mediated drug interactions with oral antidiabetic agents.